The Prescription For Better Access Podcast

New episode 🎙️ Scott Howell & Mark Hansan talk with Jonathan Blum on the future of U.S. drug policy—IRA trade-offs, 2026 Part D redesign, M3P, and balancing affordability & innovation. Must-listen for #access #coverage #drugpricing. 🎧 lnkd.in/eaCurzQb

New episode – live from ACCESS US 2025! Can we improve drug affordability without stalling innovation? Scott Howell & Mark Hansan lead a powerful convo w/ leaders from BMS, ICER, NPC & Accenture on pricing, PBMs, AI & what’s next for patient access. shorturl.at/FEd3O

Episode 29 of the podcast is now live! We called this episode The Domino Effect because so many of the challenges with #drugaccess and #affordability can be traced back to one foundational issue: benefit design. Listen now: prescriptionforbetteraccess.com/29-the-domino-…

We've got an exciting new episode coming your way next week--while you wait, don't miss our April episode with Brian Reid, MS, editor at Cost Curve. Listen here: prescriptionforbetteraccess.com/28-inside-the-…

Don't forget! This month we released an episode with #BrainReid of #CostCurve digging into his approach towards #healthcare and #drugpricing reporting. Listen here: prescriptionforbetteraccess.com/28-inside-the-…

NEW EPISODE: #DrugPricing is of the most debated — and misunderstood — issues in #healthcare. In our latest episode, we talk with Brian Reid, MS, Principal at Reid Strategic and editor of #CostCurve, one of the smartest voices cutting through the noise. bit.ly/3EsnACQ

New episode! Mark and Scott chat with Sarah Emond of ICER on patient access and the forecast for 2025! bit.ly/41aayBh

New episode! Mark and Scott chat with Sarah Emond of ICER on patient access and the forecast for 2025! bit.ly/41aayBh

New episode! Check out Mark and Scott's conversation about patient access with Sarah Emond, MPP, President and CEO of ICER. bit.ly/41aayBh #patientaccess

NEW EPISODE ALERT Sarah Emond, MPP, President & CEO of the Institute for Clinical and Economic Review (ICER), joins me and Scott Howell for a timely discussion on the challenges and opportunities in drug pricing and patient access. bit.ly/41aayBh

The Prescription for Better Access podcast (@RX4BetterAccess) interviewed ICER's President and CEO @sarahkemond. They discussed discussed ICER's new annual Launch Price and Access Report, the role of employers in drug pricing, and more. Listen now! shorturl.at/WWG0w

New podcast episode! Stacie Dusetzina, Ph.D., a leading health economist from Vanderbilt University Medical Center discusses the critical healthcare and policy trends shaping 2025. bit.ly/3BxHniT

Check out our latest conversation with Stacie Dusetzina, PhD from Vanderbilt University about critical healthcare and policy trends shaping 2025! #healthcare #patientaccess bit.ly/3BxHniT

Catch our latest episode with Stacie Dusetzina, PhD from Vanderbilt University where we discuss #drugpricing and more! bit.ly/3BxHniT

Mark and Scott interview Stacie Dusetzina, Ph.D., of Vanderbilt University about the state of drug pricing and more for 2025. Tune in here to listen: bit.ly/3BxHniT #patientaccess #drugpricing

Check out the new episode! Mark and Scott talk to Stacie Dusetzina of #VanderbiltHealth about her outlook for 2025. Listen to the episode here: bit.ly/3BxHniT

New episode! Mark Hansan and Scott Howell wrap up 2024 with Stacie Dusetzina, PhD, Professor at #VanderbiltUniversity and researcher and expert in pharmaceutical and health policy. Stacie helps us better understand the policy outlook for 2025 and beyond. bit.ly/3BxHniT

New episode! We explore the affordability and access environment for cell and gene therapies Tune in to hear Alicia Silver (Gedan), Head of Cell and Gene Therapy at #ADVIHealth, and Eric Faulkner, President of Passage Health Associates. lnkd.in/dFAjSgss

Check out our new episode about cell and gene therapy here: bit.ly/49rcvgs

Find out how global vs US pricing impacts patient access in healthcare: bit.ly/4eh97Wd